PSU Profiles
Loading...
Keywords
Last Name
Institution

Han-mou Tsai

TitleProfessor
InstitutionCollege of Medicine
DepartmentMedicine
Address500 University Drive Hershey PA 17033
Phone7175310003 x3285836
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    PREFERRED TITLE/ROLE:

    Physician, Professor of Medicine and Pathology, M. Elaine Eyster Professor of Hematology

    EDUCATION:

    Fellowship, Hematology, Montefiore Hospital and Medical Center (New York) (1988)
    Residency, Internal Medicine, Interfaith Medical Center (New York) (1985)
    M.D., National Taiwan University, College of Medicine (1979)

    NARRATIVE:

    Dr. Tsai began his career in the Hematology specialty at Montefiore Medical Center and Albert Einstein College of Medicine in New York, where he was Professor of Medicine and the Associate Head of the Unified Division of Hematology before joining Hershey Medical Center in 2008 as Professor of Medicine and Pathology and M. Elaine Eyster, M.D. Professor of Hematology. Dr. Tsai is an international renowned clinician-scientist with major contribution to advancing the understanding of a serious clotting disorder, thrombotic thrombocytoepepnic purpura (TTP). He has served as members of sientific committees and advisory or editorial boards of the American Society of Hematology, Congresses of the International Society of Thrombosis and Hemostasis and major medical journals including Haematologica/The European Hematology Association Journal and Journal of Thrombosis and Hemostasis/The Journal of International Society of Thrombosis and Haemostasis. He is also a chapter author of the textbook Wintrobe's Clinical Hematology, 12/e.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Tsai HM, Kuo E. From Gestational Hypertension and Preeclampsia to Atypical Hemolytic Uremic Syndrome. Obstet Gynecol. 2016 May; 127(5):907-10. PMID: 27054930.
      View in: PubMed
    2. Tsai HM, Kuo E. Eculizumab therapy leads to rapid resolution of thrombocytopenia in atypical hemolytic uremic syndrome. Adv Hematol. 2014; 2014:295323. PMID: 25400666; PMCID: PMC4221969.
    3. Tsai HM. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome. Transfus Med Rev. 2014 Oct; 28(4):187-97. PMID: 25280590.
      View in: PubMed
    4. Tsai HM. Thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: an update. Hematol Oncol Clin North Am. 2013 Jun; 27(3):565-84. PMID: 23714312.
      View in: PubMed
    5. Tsai E, Chapin J, Laurence JC, Tsai HM. Use of eculizumab in the treatment of a case of refractory, ADAMTS13-deficient thrombotic thrombocytopenic purpura: additional data and clinical follow-up. Br J Haematol. 2013 Aug; 162(4):558-9. PMID: 23692124; PMCID: PMC3720712.
    6. Chapin J, Eyler S, Smith R, Tsai HM, Laurence J. Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood. 2013 May 09; 121(19):4012-3. PMID: 23660864.
      View in: PubMed
    7. Tsai HM. Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med. 2013 Mar; 126(3):200-9. PMID: 23410558.
      View in: PubMed
    8. Tsai HM. Autoimmune thrombotic microangiopathy: advances in pathogenesis, diagnosis, and management. Semin Thromb Hemost. 2012 Jul; 38(5):469-82. PMID: 22473663.
      View in: PubMed
    9. Tsai HM. von Willebrand factor, shear stress, and ADAMTS13 in hemostasis and thrombosis. ASAIO J. 2012 Mar-Apr; 58(2):163-9. PMID: 22370688.
      View in: PubMed
    10. Tsai HM. Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time? Kidney Int. 2010 Feb; 77(4):267-9. PMID: 20118898; PMCID: PMC3153079.
    11. Tsai HM. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol. 2010 Jan; 91(1):1-19. PMID: 20058209; PMCID: PMC3159000.
    12. Tsai HM. Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura. Kidney Int Suppl. 2009 Feb; (112):S11-4. PMID: 19180123; PMCID: PMC3158997.
    13. Zhou W, Tsai HM. N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity. Blood. 2009 Jan 22; 113(4):929-35. PMID: 18981290; PMCID: PMC2630278.
    14. Dong L, Chandrasekaran V, Zhou W, Tsai HM. Evolution of ADAMTS13 antibodies in a fatal case of thrombotic thrombocytopenic purpura. Am J Hematol. 2008 Oct; 83(10):815-7. PMID: 18661493; PMCID: PMC2574606.
    15. Tsai HM. The kidney in thrombotic thrombocytopenic purpura. Minerva Med. 2007 Dec; 98(6):731-47. PMID: 18299685; PMCID: PMC2430013.
    16. Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007 Aug; 21(4):609-32, v. PMID: 17666281; PMCID: PMC2001253.
    17. Zhou W, Bouhassira EE, Tsai HM. An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood. 2007 Aug 01; 110(3):886-93. PMID: 17426255; PMCID: PMC1924774.
    18. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr. 2007 Mar; 166(3):249-57. PMID: 17187257; PMCID: PMC1820762.
    19. Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther. 2006 Nov; 4(6):813-25. PMID: 17173498; PMCID: PMC2435177.
    20. Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006 Jul; 70(1):16-23. PMID: 16760911; PMCID: PMC2497001.
    21. Hirata S, Okamoto H, Ohta S, Kobashigawa T, Uesato M, Kawaguchi Y, Tateishi M, Hara M, Kamatani N, Tsai HM. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura in the setting of adult-onset Still's disease. Rheumatology (Oxford). 2006 Aug; 45(8):1046-7. PMID: 16720635; PMCID: PMC3152946.
    22. Tsai HM, Raoufi M, Zhou W, Guinto E, Grafos N, Ranzurmal S, Greenfield RS, Rand JH. ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura. Thromb Haemost. 2006 May; 95(5):886-92. PMID: 16676082; PMCID: PMC2603189.
    23. Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006; 57:419-36. PMID: 16409158; PMCID: PMC2426955.
    24. Tsai HM. Measurement of ADAMTS13. Int Rev Thromb. 2006; 1(4):272-280. PMID: 26478757.
      View in: PubMed
    25. Zhou W, Dong L, Ginsburg D, Bouhassira EE, Tsai HM. Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy? J Biol Chem. 2005 Dec 02; 280(48):39934-41. PMID: 16203734; PMCID: PMC2582217.
    26. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005 Oct; 115(10):2752-61. PMID: 16200209; PMCID: PMC1240119.
    27. Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005 Jun; 85(6):780-8. PMID: 15806136; PMCID: PMC2573995.
    28. Tsai HM. Why Do We Need ADAMTS13? Nihon Kessen Shiketsu Gakkai shi. 2005; 16(1):54-69. PMID: 21709769.
      View in: PubMed
    29. Tsai HM. Type 2 A (group II) von Willebrand disease mutations increase the susceptibility of VWF to ADAMTS-13. J Thromb Haemost. 2004 Nov; 2(11):2057. PMID: 15550049.
      View in: PubMed
    30. Tsai HM. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2004 Oct; 30(5):549-57. PMID: 15497097.
      View in: PubMed
    31. Tsai HM. A journey from sickle cell anemia to ADAMTS13. J Thromb Haemost. 2004 Sep; 2(9):1510-4. PMID: 15333022.
      View in: PubMed
    32. Schiff DE, Roberts WD, Willert J, Tsai HM. Thrombocytopenia and severe hyperbilirubinemia in the neonatal period secondary to congenital thrombotic thrombocytopenic purpura and ADAMTS13 deficiency. J Pediatr Hematol Oncol. 2004 Aug; 26(8):535-8. PMID: 15284596.
      View in: PubMed
    33. Zhou W, Tsai HM. An enzyme immunoassay of ADAMTS13 distinguishes patients with thrombotic thrombocytopenic purpura from normal individuals and carriers of ADAMTS13 mutations. Thromb Haemost. 2004 Apr; 91(4):806-11. PMID: 15045144.
      View in: PubMed
    34. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004 Mar; 124(6):787-95. PMID: 15009067; PMCID: PMC3153075.
    35. Downes KA, Yomtovian R, Tsai HM, Silver B, Rutherford C, Sarode R. Relapsed thrombotic thrombocytopenic purpura presenting as an acute cerebrovascular accident. J Clin Apher. 2004; 19(2):86-9. PMID: 15274201.
      View in: PubMed
    36. Tsai HM. Shear stress and von Willebrand factor in health and disease. Semin Thromb Hemost. 2003 Oct; 29(5):479-88. PMID: 14631548.
      View in: PubMed
    37. Tsai HM. Deficiency of ADAMTS-13 in thrombotic and thrombocytopenic purpura. J Thromb Haemost. 2003 Sep; 1(9):2038-40; discussion 2040-5. PMID: 12941048.
      View in: PubMed
    38. Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 2003 Apr; 14(4):1072-81. PMID: 12660343.
      View in: PubMed
    39. Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003 Apr; 1(4):625-31. PMID: 12871390.
      View in: PubMed
    40. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003 Mar; 70(3):183-5. PMID: 12605663.
      View in: PubMed
    41. Savasan S, Lee SK, Ginsburg D, Tsai HM. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood. 2003 Jun 01; 101(11):4449-51. PMID: 12576319.
      View in: PubMed
    42. Tsai HM. Platelet activation and the formation of the platelet plug: deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol. 2003 Mar 01; 23(3):388-96. PMID: 12615692.
      View in: PubMed
    43. Forman RB, Benkel SA, Novik Y, Tsai HM. Presence of ADAMTS13 activity in a patient with metastatic cancer and thrombotic microangiopathy. Acta Haematol. 2003; 109(3):150-2. PMID: 12714826.
      View in: PubMed
    44. Jubinsky PT, Moraille R, Tsai HM. Thrombotic thrombocytopenic purpura in a newborn. J Perinatol. 2003 Jan; 23(1):85-7. PMID: 12556937.
      View in: PubMed
    45. Tarr PI, Tsai HM, Chandler WL. Thrombotic microangiopathies. N Engl J Med. 2002 Dec 26; 347(26):2171-3; author reply 2171-3. PMID: 12501862.
      View in: PubMed
    46. Tsai HM. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Blood. 2002 Nov 15; 100(10):3839-40; author reply 3840-2. PMID: 12411328.
      View in: PubMed
    47. Tsai HM. Deficiency of ADAMTS13 and thrombotic thrombocytopenic purpura. Transfusion. 2002 Nov; 42(11):1523-4; author reply 1524-5. PMID: 12421229.
      View in: PubMed
    48. Tsai HM, Sarode R, Downes KA. Ultralarge von Willebrand factor multimers and normal ADAMTS13 activity in the umbilical cord blood. Thromb Res. 2002 Nov 01; 108(2-3):121-5. PMID: 12590947.
      View in: PubMed
    49. Pham PT, Danovitch GM, Wilkinson AH, Gritsch HA, Pham PC, Eric TM, Kendrick E, Charles LR, Tsai HM. Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. Transplantation. 2002 Oct 27; 74(8):1077-80. PMID: 12438949.
      View in: PubMed
    50. Tsai HM. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura. J Mol Med (Berl). 2002 Oct; 80(10):639-47. PMID: 12395148.
      View in: PubMed
    51. Tsai HM. Deficiency of ADAMTS13 in thrombotic thrombocytopenic purpura. Int J Hematol. 2002 Aug; 76 Suppl 2:132-8. PMID: 12430913.
      View in: PubMed
    52. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis. 2002 May-Jun; 28(3):385-91. PMID: 12367582.
      View in: PubMed
    53. Tsai HM, Tarr PI. Rebuttal to: von Willebrand factor-cleaving protease in childhood diarrhoea-associated haemolytic uraemic syndrome. Thromb Haemost. 2002 Mar; 87(3):548-9; author's reply 549-50. PMID: 11916096.
      View in: PubMed
    54. Robson WL, Tsai HM. Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics. 2002 Feb; 109(2):322-5. PMID: 11826215.
      View in: PubMed
    55. Morgensztern D, Kharfan-Dabaja MA, Tsai HM, Lian EC. Warm-antibody autoimmune hemolytic anemia developing after thrombotic thrombocytopenic purpura. Acta Haematol. 2002; 108(3):154-6. PMID: 12373088.
      View in: PubMed
    56. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001 Oct 04; 413(6855):488-94. PMID: 11586351.
      View in: PubMed
    57. Tsai HM, Chandler WL, Sarode R, Hoffman R, Jelacic S, Habeeb RL, Watkins SL, Wong CS, Williams GD, Tarr PI. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatr Res. 2001 May; 49(5):653-9. PMID: 11328948.
      View in: PubMed
    58. O'Brien JR, Tsai HM, Etherington MD. A comparison of von Willebrand Factor antigen with platelet activity in vitro in normal and venous occlusion blood. Platelets. 2001 Feb; 12(1):27-33. PMID: 11281627.
      View in: PubMed
    59. Tsai HM, Li A, Rock G. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab. 2001; 47(7-8):387-92. PMID: 11499801.
      View in: PubMed
    60. Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM. Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy. Hematol J. 2001; 2(5):292-9. PMID: 11920264.
      View in: PubMed
    61. O'Brien JR, Tsai HM, Etherington MD. Defective von willebrand factor activity detected by the filterometer in three clinical conditions. Platelets. 2000 Nov; 11(7):388-94. PMID: 11132105.
      View in: PubMed
    62. Tsai HM. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol. 2000 Nov; 65(3):251-5. PMID: 11074544.
      View in: PubMed
    63. Bennett CL, Connors JM, Carwile JM, Moake JL, Bell WR, Tarantolo SR, McCarthy LJ, Sarode R, Hatfield AJ, Feldman MD, Davidson CJ, Tsai HM. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000 Jun 15; 342(24):1773-7. PMID: 10852999.
      View in: PubMed
    64. Tsai HM, Rice L, Sarode R, Chow TW, Moake JL. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med. 2000 May 16; 132(10):794-9. PMID: 10819702; PMCID: PMC3152977.
    65. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998 Nov 26; 339(22):1585-94. PMID: 9828246; PMCID: PMC3159001.
    66. Lankhof H, Damas C, Schiphorst ME, Ijsseldijk MJ, Bracke M, Furlan M, Tsai HM, de Groot PG, Sixma JJ, Vink T. von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost. 1997 May; 77(5):1008-13. PMID: 9184419.
      View in: PubMed
    67. Tsai HM, Sussman II, Ginsburg D, Lankhof H, Sixma JJ, Nagel RL. Proteolytic cleavage of recombinant type 2A von Willebrand factor mutants R834W and R834Q: inhibition by doxycycline and by monoclonal antibody VP-1. Blood. 1997 Mar 15; 89(6):1954-62. PMID: 9058716.
      View in: PubMed
    68. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood. 1996 May 15; 87(10):4235-44. PMID: 8639782.
      View in: PubMed
    69. Tsai HM, Sussman II, Nagel RL. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood. 1994 Apr 15; 83(8):2171-9. PMID: 8161783.
      View in: PubMed
    70. Kaul DK, Nagel RL, Chen D, Tsai HM. Sickle erythrocyte-endothelial interactions in microcirculation: the role of von Willebrand factor and implications for vasoocclusion. Blood. 1993 May 01; 81(9):2429-38. PMID: 8481522.
      View in: PubMed
    71. Tsai HM, Nagel RL, Hatcher VB, Sussman II. Multimeric composition of endothelial cell-derived von Willebrand factor. Blood. 1989 Jun; 73(8):2074-6. PMID: 2786433.
      View in: PubMed
    Tsai's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _